Pemetrexed in Advanced Non-small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01193959 |
Recruitment Status : Unknown
Verified September 2010 by Istituto Clinico Humanitas.
Recruitment status was: Active, not recruiting
First Posted : September 2, 2010
Last Update Posted : October 13, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Non-small Cell Lung Cancer (NSCLC) |
Study Type : | Observational |
Estimated Enrollment : | 33 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer |
Study Start Date : | September 2010 |
Estimated Primary Completion Date : | September 2010 |
Estimated Study Completion Date : | September 2011 |

- Association of each biomarker with treatment outcome in terms of response rate, time to progression, overall survival. [ Time Frame: one year ]
- Association of each biomarker with clinico-pathological features: histology, gender, age, smoking status, response to previous chemotherapy. [ Time Frame: one year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor tissue available at our institution
- Patients treated with single agent pemetrexed for metastatic disease
- Availability of full clinical data
Exclusion Criteria:
- Cytological diagnosis of advanced Non-small cell lung cancer
- Lack of tumor tissue at our institution
- Lack of full clinical data

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01193959
Italy | |
Istituto Clinico Humanitas | |
Rozzano, Milano, Italy, 20089 |
Principal Investigator: | Armando SANTORO, MD | Istituto Clinico Humanitas |
Responsible Party: | Armando Santoro, MD, Istituto Clinico Humanitas |
ClinicalTrials.gov Identifier: | NCT01193959 |
Other Study ID Numbers: |
ONC/OSS-02/2010 |
First Posted: | September 2, 2010 Key Record Dates |
Last Update Posted: | October 13, 2010 |
Last Verified: | September 2010 |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |